Sanofi Genzyme has expanded its Multiple Myeloma Journey Partners Program, which uses storytelling to improve its multiple myeloma patients’ outcomes as they cope with the second most common blood cancer worldwide.
Journey Partners includes multiple myeloma patients who have had similar emotions, challenges and questions about life with multiple myeloma, the company said in a March 22 press release.
The program expansion aims to boost its reach and awareness, with the goal of holding more programs and educating additional patients and caregivers in local communities across the United States, according to Sanofi Genzyme, the specialty care global business unit of Sanofi.
The free Multiple Myeloma Journey Partners program is an hour-long educational seminar that gives multiple myeloma patients and their caregivers a chance to hear others talk about their individual journey with multiple myeloma while "undergoing an autologous stem cell transplant (ASCT), considered a first-line treatment and the standard of care for treating multiple myeloma in eligible patients,” Sanofi Genzyme said.
During the seminar, patients and their caregivers are also educated about useful resources and why it’s important to consider undergoing a transplant evaluation, according to Cambridge, Mass.-based Sanofi Genzyme.
"Sanofi Genzyme created the Multiple Myeloma Journey Partners Program to let multiple myeloma patients know they are not alone and to provide educational resources and services that help patients and families navigate their journey to achieve the best possible outcomes," Bhavesh Ashar, general manager of US Oncology, Sanofi Genzyme, said in the release. "As a company, we value the importance of taking a holistic approach to patient care and transforming the patient experience. There's a real power in telling and listening to personal narratives. It helps increase the knowledge base of patients and caregivers and makes them feel supported."
